Helicobacter pylori masks differences in homocysteine plasma levels between controls and type 2 diabetic patients

European Journal of Clinical Investigation

Volumn 32, Issue 3, 2002, Pages 158-162

  Cenerelli, S ^a   Bonazzi, P ^b   Galeazzi, R ^b   Testa, I ^c   Bonfigli, A R ^d   Sirolla, C ^d   Giunta, S ^d   Galeazzi, L ^d   Fumelli, D ^a   Testa, Roberto ^d  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b General Hospital   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d INRCA   (Italy)

Author keywords

Helicobacter pylori; Homocysteine; Type 2 diabetes mellitus

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CARBON 13; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC ANGIOPATHY; FEMALE; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; METABOLISM; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PARAMETER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; UREA BREATH TEST;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOMOCYSTEINE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION;

EID: 0036995168     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.00962.x     Document Type: Article

References (34)

1. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992;12:279-8.
2. Malinow MR. Homocyst (e) ine and arterial occlusive diseases. J Intern Med 1994;236:603-17.
3. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med 1974;291:537-43.
4. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980;18:113-21.
5. Blundell G, Jones BG, Rose FA, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996;122:163-72.
6. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 1984;74:1890-4.
7. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262:10098-103.
8. Olszewski AJ, McCully KS. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med 1993;683-93.
9. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1991;91:308-18.
10. Munshi MN, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996;45:133-5.
11. Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000;23:1816-22.
12. Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM et al. Serum homocysteine levels are associated with the development of (micro) albuminuria: the Hoorn study. Arterioscler Thromb Vasc Biol 2001;21:74-81.
13. Fonseca V, Dicker-Brown A, Ranganathan S, Song W, Barnard RJ, Fink L et al. Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism 2000;49:736-41.
14. Jacobs RL, House JD, Brosnan ME, Brosnan JT. Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Diabetes 1998;47:1967-70.
15. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998;18:133-8.
16. Pixa A, Pietzsch J, Julius U, Menschikowski M, Hanefeld M. Impaired glucose tolerance (IGT) is not associated with disturbed homocysteine metabolism. Amino Acids 2000;18:289-98.
17. Kang SS, Wong PW, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987;36:458-62.
18. 6 on fasting plasma homocysteine concentrations. J Am J Clin Nutr 1992;55:1154-60.
19. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J 1993;7:1344-53.
20. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. Off Arch Intern Med 1998;158:1301-6.
21. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997;96:1745-9.
22. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
23. 12 deficiency? Arch Intern Med 2000;160:1349-53.
24. Nilsson HO, Taneera J, Castedal M, Glatz E, Olsson R, Wadstrom T. Identification of Helicobacter pylori and journal Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. J Clin Microbiol 2000;38:1072-6.
25. Avenaud P, Marais A, Monteiro L, Le Bail B, Bioulac Sage P, Balabaud C et al. Detection of Helicobacter species in the liver of patients with and without primary liver carcinoma. Cancer 2000;89:1431-9.
26. Cremonini F, Gasbarrini A, Armuzzi A, Gasbarrini G. Helicobacter pylori-related diseases. Eur J Clin Invest 2001;31:431-7.
27. Gasbarrini G, Pretolani S, Bonvicini F, Gatto MR, Tonelli E, Megraud F et al. A population based study of Helicobacter pylori infection in a European country: the San Marino Study. Relations with gastrointestinal diseases. Gut 1995;36:838-44.
28. Rothenbacher D, Bode G, Peschke F, Berg G, Adler G, Brenner H. Active infection with Helicobacter pylori in an asymptomatic population of middle aged to elderly people. Epidemiol Infect 1998;120:297-303.
29. Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
30. Ligthart GJ, Corberand JX, Fournier C, Galanaud P, Hijman W, Kennes B et al. Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mech Ageing Dev 1984;28:47-55.
31. Savarino V, Vigneri S, Celle G. The 13C urea breath test in the diagnosis of Helicobacter pylori infection. Gut 1999;45:118-22.
32. Cornwell PE, Morgan SL, Vaughn WH. Modification of a high-performance liquid chromatographic method for assay of homocysteine in human plasma. J Chromatogr B Biomed Appl 1993;617:136-9.
33. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:17-20.
34. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JCM et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. Arch Intern Med 1999;159:38-44.